Publications by authors named "M P Kolinsky"
Background: Neuroendocrine prostate cancer (NEPC) encompasses pure NEPC and tumors with mixed adenocarcinoma and neuroendocrine histology. While NEPC is thought to confer a poor prognosis, outcome data are sparse, making risk stratification and treatment decisions difficult for clinicians.
Methods: This retrospective study identified patients with morphological and/or immunohistochemical NEPC features on pathological review of high-grade prostate cancer cases.
Background: The management of advanced prostate cancer continues to evolve rapidly, particularly with the earlier use of survival-prolonging therapies in metastatic castration-sensitive prostate cancer (mCSPC). Though approved prior to the use of intensification therapy in mCSPC, taxane-based chemotherapies remain a relevant option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, there is little evidence determining the outcomes of taxane chemotherapies as the first subsequent taxane (FST) in mCRPC pts who received docetaxel intensification (DI) in mCSPC.
View Article and Find Full Text PDFBackground: Data are needed to improve the current understanding of clinical management and characteristics of patients with advanced prostate cancer (PC) treated with androgen receptor pathway inhibition (ARPI) therapy.
Methods: This retrospective cohort study using real-world, population-level data from Alberta, Canada included all individuals diagnosed in 2017-2020 with de novo metastatic castration-sensitive PC (mCSPC) or nonmetastatic castration-resistant PC (nmCRPC) who initiated androgen deprivation therapy (ADT). For mCSPC, patients were classified as ARPI-exposed if they received an ARPI within 180 days of initiating ADT, while patients with nmCRPC were classified as ARPI-exposed if they received an ARPI within 2 years of diagnosis.
Article Synopsis
- High-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT) is a standard treatment for patients with metastatic germ cell tumors (mGCTs) who relapse after conventional chemo, and this study reviews its effectiveness in Alberta, Canada, over 20 years.
- A review of 43 patients treated with HDC-ASCT revealed a median age of 28, with most having non-seminoma tumors; survival rates showed 42% were disease-free at last follow-up.
- The findings suggest that HDC-ASCT is an effective second-line therapy for mGCT, with indications that tandem transplants may yield better outcomes, though the results are limited by a small sample size.